K Y Smith

Summary

Affiliation: Rush University Medical Center
Country: USA

Publications

  1. ncbi request reprint Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy
    K Y Smith
    Section of Infectious Diseases, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    J Infect Dis 181:141-7. 2000
  2. pmc Initiating antiretroviral therapy in asymptomatic HIV patients
    Kimberly Y Smith
    Rush Medical College, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60614, USA
    J Natl Med Assoc 96:13S-16S. 2004
  3. pmc Disparities and gaps in HIV research and care
    Kimberly Y Smith
    Rush Medical College, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60614, USA
    J Natl Med Assoc 96:5S-7S. 2004
  4. ncbi request reprint Optimizing care for African-American HIV-positive patients
    Kimberly Y Smith
    Rush Medical College and Rush Presbyterian St Luke s Medical Center, Chicago, Illinois, USA
    AIDS Patient Care STDS 17:527-38. 2003
  5. ncbi request reprint Protease inhibitor-sparing regimens
    Kimberly Y Smith
    Department of Medicine, Rush Medical College, Rush Presbyterian St Luke s Medical Center, Chicago, USA
    J Int Assoc Physicians AIDS Care (Chic) 1:116-20. 2002
  6. pmc Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174
    Kimberly Smith
    Section of Infectious Diseases, Rush University Medical Center, Chicago, Illinois 60612, USA
    AIDS Res Hum Retroviruses 26:425-32. 2010
  7. ncbi request reprint Selected metabolic and morphologic complications associated with highly active antiretroviral therapy
    Kimberly Y Smith
    Section of Infectious Diseases, Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
    J Infect Dis 185:S123-7. 2002
  8. ncbi request reprint T cell receptor excision circle (TREC) content following maximum HIV suppression is equivalent in HIV-infected and HIV-uninfected individuals
    C M Steffens
    Department of Immunology/Microbiology, Rush-Presbyterian-St Luke's Medical Center, Chicago, Illinois 60612, USA
    AIDS 15:1757-64. 2001
  9. ncbi request reprint Evaluation of the impact of highly active antiretroviral therapy on immune recovery in antiretroviral naive patients
    L Al-Harthi
    Department of Immunology Microbiology, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    HIV Med 5:55-65. 2004
  10. doi request reprint Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment
    Kimberly Y Smith
    Rush University Medical Center, Chicago, Illinois 60612, USA
    AIDS 23:1547-56. 2009

Research Grants

Collaborators

Detail Information

Publications20

  1. ncbi request reprint Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy
    K Y Smith
    Section of Infectious Diseases, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    J Infect Dis 181:141-7. 2000
    ..These findings suggest that there is a complex relationship among the thymus, viral replication, and lymphocyte restoration after application of HAART in HIV disease...
  2. pmc Initiating antiretroviral therapy in asymptomatic HIV patients
    Kimberly Y Smith
    Rush Medical College, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60614, USA
    J Natl Med Assoc 96:13S-16S. 2004
  3. pmc Disparities and gaps in HIV research and care
    Kimberly Y Smith
    Rush Medical College, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60614, USA
    J Natl Med Assoc 96:5S-7S. 2004
  4. ncbi request reprint Optimizing care for African-American HIV-positive patients
    Kimberly Y Smith
    Rush Medical College and Rush Presbyterian St Luke s Medical Center, Chicago, Illinois, USA
    AIDS Patient Care STDS 17:527-38. 2003
    ....
  5. ncbi request reprint Protease inhibitor-sparing regimens
    Kimberly Y Smith
    Department of Medicine, Rush Medical College, Rush Presbyterian St Luke s Medical Center, Chicago, USA
    J Int Assoc Physicians AIDS Care (Chic) 1:116-20. 2002
  6. pmc Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174
    Kimberly Smith
    Section of Infectious Diseases, Rush University Medical Center, Chicago, Illinois 60612, USA
    AIDS Res Hum Retroviruses 26:425-32. 2010
    ..Treatment with rhGH +ART may be associated with modest increases in CD4 lymphocytes over ART alone in subjects with CD4 <350, yet the origin of these naive cells and their impact on immune function require further investigation...
  7. ncbi request reprint Selected metabolic and morphologic complications associated with highly active antiretroviral therapy
    Kimberly Y Smith
    Section of Infectious Diseases, Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
    J Infect Dis 185:S123-7. 2002
    ..Treatment regimens directed at these abnormalities are being developed, but clinical trials are needed to fully ascertain the efficacy and safety of such interventions...
  8. ncbi request reprint T cell receptor excision circle (TREC) content following maximum HIV suppression is equivalent in HIV-infected and HIV-uninfected individuals
    C M Steffens
    Department of Immunology/Microbiology, Rush-Presbyterian-St Luke's Medical Center, Chicago, Illinois 60612, USA
    AIDS 15:1757-64. 2001
    ....
  9. ncbi request reprint Evaluation of the impact of highly active antiretroviral therapy on immune recovery in antiretroviral naive patients
    L Al-Harthi
    Department of Immunology Microbiology, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    HIV Med 5:55-65. 2004
    ..To examine the extent of immune reconstitution in treatment-naive patients with CD4 T-cell counts <500 cells/microL following 48 weeks of highly active antiretroviral therapy (HAART)...
  10. doi request reprint Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment
    Kimberly Y Smith
    Rush University Medical Center, Chicago, Illinois 60612, USA
    AIDS 23:1547-56. 2009
    ..This is the first completed, randomized clinical trial to directly compare the efficacy, safety, and tolerability of these agents, each in combination with lopinavir/ritonavir in antiretroviral-naive patients...
  11. ncbi request reprint HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course
    Allan R Tenorio
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    J Acquir Immune Defic Syndr 34:491-6. 2003
    ..HIV-specific CD4+ T-cell immunity was detected in most subjects with low-level and undetectable viremia and may have a role in controlling viremia in the setting of partial suppression...
  12. doi request reprint Classic pyomyositis of the extremities as an unusual manifestation of Blastomyces dermatitidis: a report of two cases
    Michael Y Lin
    Section of Infectious Diseases, Rush University Medical Center, Chicago, IL 60612, USA
    Mycoses 53:356-9. 2010
    ..dermatitidis, particularly of the extremity muscles, is unique. We conclude that B. dermatitidis is a potential cause of classic pyomyositis...
  13. ncbi request reprint A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia
    Joyce K Keithley
    Rush University College of Nursing, Chicago, Illinois 60612, USA
    Nutrition 18:201-4. 2002
    ..We collected preliminary safety and efficacy data on the effects of Cholestin, a statin-containing dietary supplement, in individuals with dsylipidemia related to human immunodeficiency virus...
  14. ncbi request reprint Electron beam computed tomography for assessment of coronary artery disease in HIV-infected men receiving antiretroviral therapy
    Rohit Talwani
    Section of Infectious Diseases, Department of Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    J Acquir Immune Defic Syndr 30:191-5. 2002
    ..These results need to be confirmed in larger long-term studies, with controls well matched for coronary risk factors...
  15. ncbi request reprint Recognizing and managing common toxicities in patients receiving antiretroviral therapy
    M Keith Rawlings
    Peabody Health Center, Dallas, Texas, USA
    AIDS Read 14:S12-5. 2004
    ..An understanding of the drug-specific, class-specific, and general toxicities and side effects of antiretroviral drugs will help the clinician tailor treatment regimens to individual patients...
  16. ncbi request reprint Role of Baseline pol Genotype in HIV-1 Fitness Evolution
    Jan Weber
    Department of Virology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Acquir Immune Defic Syndr 33:448-60. 2003
    ..65, P < 0.0001). However, our results suggest that the preexistence of secondary mutations in protease genetic background may have implications in HIV-1 fitness evolution and virologic response to antiretroviral therapy...
  17. ncbi request reprint Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease
    Hernan Valdez
    Case Western Reserve University, University Hospitals of Cleveland Center for AIDS Research, Ohio, USA
    AIDS 16:1859-66. 2002
    ..To describe the magnitude of immune restoration after long-term control of HIV-1 replication. DESIGN Prospective study of immune restoration in patients starting highly active antiretroviral therapy (HAART)...
  18. ncbi request reprint Immune reconstitution after successful treatment with protease inhibitor-based and protease inhibitor-sparing antiretroviral regimens
    Kimberly Y Smith
    J Acquir Immune Defic Syndr 29:544-5. 2002
  19. pmc Improving adherence to HAART
    Valerie E Stone
    Massachusetts General Hospital, Boston, MA 02114, USA
    J Natl Med Assoc 96:27S-29S. 2004
  20. ncbi request reprint CCR5 and CXCR4 expression after highly active antiretroviral therapy (HAART)
    Kimberly Y Smith
    J Acquir Immune Defic Syndr 30:458-60. 2002

Research Grants1

  1. Growth Hormone and Immune Reconstitution in HIV Disease
    Kimberly Smith; Fiscal Year: 2004
    ..abstract_text> ..